RxIndia
Loading clinical data...
Loading clinical data...
Authoritative Clinical Reference
| Property | Benzylpenicillin Sodium/Potassium (“Crystalline Penicillin”) | Procaine Benzylpenicillin (“Procaine Penicillin G”) | Benzathine Benzylpenicillin (“Benzathine Penicillin G”) |
|
Route
|
IV (preferred) or IM
|
IM ONLY
|
IM ONLY
|
|
Duration of action
|
Short-acting (~4–6 hours per dose) | Intermediate depot (~12–24 hours) | Long-acting depot (~3–4 weeks) |
|
Peak levels
|
IV: immediate; IM: 15–30 min | IM: 1–4 hours (lower peak than crystalline) | IM: 24–48 hours (very low peak) |
|
Achieves high serum levels?
|
✅ YES — high peak concentrations | Moderate | ⛔ NO — only low sustained levels |
|
Achieves CSF levels?
|
✅ YES (with inflamed meninges) | ⛔ INADEQUATE | ⛔ INADEQUATE |
|
Can be given IV?
|
✅ YES |
⛔ NEVER — FATAL RISK (Hoigné reaction; cardiopulmonary arrest)
|
⛔ NEVER — FATAL RISK (embolic cardiopulmonary arrest)
|
|
Typical use
|
Serious infections: meningitis, endocarditis, severe pneumonia, gas gangrene, neurosyphilis | Uncomplicated pneumonia, mild-moderate infections, congenital syphilis (when IV not feasible) | RF/RHD secondary prophylaxis, early syphilis (non-neurological), congenital syphilis prophylaxis |
| Salt Form | Permitted Routes | Forbidden Routes |
|
Benzylpenicillin sodium/potassium (Crystalline Penicillin)
|
IV (bolus or infusion — preferred); IM (acceptable)
|
— |
|
Procaine benzylpenicillin (Procaine Penicillin)
|
IM only (deep intramuscular)
|
⛔ NEVER IV — risk of Hoigné reaction (pseudo-anaphylaxis), cardiac arrest
|
|
Benzathine benzylpenicillin (Benzathine Penicillin)
|
IM only (deep intramuscular into large muscle)
|
⛔ NEVER IV — risk of embolic cardiopulmonary arrest, death
|
| Dosage Form | Strengths Available | Notes |
| Powder for injection (vial) — for reconstitution before IV or IM use |
5 lakh units (500,000 IU; ~300 mg)
|
Commonly available. Suitable for paediatric dosing. |
|
10 lakh units (1,000,000 IU = 1 MU; ~600 mg)
|
Most commonly stocked strength in Indian hospitals. | |
|
20 lakh units (2,000,000 IU = 2 MU; ~1,200 mg)
|
Available; used for adult high-dose regimens. | |
|
50 lakh units (5,000,000 IU = 5 MU; ~3,000 mg)
|
Available at larger centres; reduces the number of vials needed for high-dose therapy (meningitis, endocarditis). |
| Dosage Form | Strengths Available | Notes |
|
Powder for suspension / pre-constituted suspension (vial) — for IM injection ONLY
|
4 lakh units (400,000 IU) per vial
|
Standard vial. Aqueous suspension — shake well before use. |
|
3 lakh units (300,000 IU) per mL in some formulations
|
Check specific product concentration. |
| Dosage Form | Strengths Available | Notes |
|
Powder for suspension (vial) — for IM injection ONLY
|
6 lakh units (600,000 IU) per vial
|
Paediatric dose vial. |
|
12 lakh units (1,200,000 IU = 1.2 MU) per vial
|
Standard adult dose vial for RF prophylaxis and early syphilis. The most commonly prescribed strength.
|
|
|
24 lakh units (2,400,000 IU = 2.4 MU) per vial
|
Used for syphilis treatment (given as single dose or divided between two injection sites). Available but less commonly stocked than the 1.2 MU vial. |
| FDC | Components | Notes |
|
Fortified Procaine Penicillin (FPP)
|
Crystalline penicillin (benzylpenicillin sodium) + Procaine penicillin in same vial (various ratios — e.g., 1 lakh crystalline + 3 lakh procaine) | IM only. Widely available. Provides initial high levels (from crystalline component) plus sustained depot effect (from procaine component). Commonly used for community-acquired pneumonia, cellulitis, and soft tissue infections where IM is the only available route. |
| Parameter | Value |
|
Bioavailability (oral)
|
⛔ Negligible — benzylpenicillin is acid-labile; destroyed by gastric acid. Oral administration is NOT effective. No oral formulation exists.
|
|
Bioavailability (IM — crystalline)
|
Near-complete absorption from IM site; peak in 15–30 minutes. |
|
Bioavailability (IM — procaine salt)
|
Slow, sustained absorption from IM depot; peak in 1–4 hours; therapeutic levels maintained for approximately 12–24 hours. |
|
Bioavailability (IM — benzathine salt)
|
Very slow absorption from IM depot; peak at 24–48 hours (low peak concentration); low but sustained treponemicidal levels maintained for approximately 3–4 weeks. |
|
Tmax
|
IV: immediate. IM crystalline: 15–30 min. IM procaine: 1–4 hours. IM benzathine: 24–48 hours.
|
|
Protein binding
|
Approximately 60% (moderate). Bound primarily to albumin.
|
|
Volume of distribution (Vd)
|
Approximately 0.3–0.4 L/kg (relatively low — distributes primarily in extracellular fluid). Penetrates well into most body tissues and fluids EXCEPT: eye (poor), CSF (poor with intact meninges; improved with inflamed meninges — see below), and prostatic fluid (poor).
|
|
CSF penetration
|
⚠️ Critical parameter for meningitis treatment. With intact meninges: ~1–2% of serum level (clinically inadequate). With inflamed meninges (meningitis): ~5–10% of serum level — sufficient when high IV doses are used (achieves therapeutic CSF concentrations of >0.06 mcg/mL against susceptible organisms). ⛔ Procaine penicillin and benzathine penicillin do NOT achieve adequate CSF levels even with inflamed meninges — the peak serum concentrations are too low. Only high-dose IV crystalline penicillin is suitable for meningitis and neurosyphilis.
|
|
Metabolism
|
Minimal hepatic metabolism (~10–20%). The beta-lactam ring undergoes some hydrolysis to penicilloic acid (inactive). Not dependent on CYP450 enzymes. Benzylpenicillin is NOT a significant CYP450 inhibitor, inducer, or substrate.
|
|
Drug transporter relevance
|
Benzylpenicillin is a substrate of OAT1 and OAT3 (organic anion transporters) in the renal tubule — these mediate active tubular secretion. This is the basis for the probenecid interaction (probenecid inhibits OAT-mediated tubular secretion → increases penicillin levels). Also a substrate of OAT at the choroid plexus (actively transported OUT of CSF → contributes to low CSF levels).
|
|
Active metabolites
|
None. Penicilloic acid (hydrolysis product) is inactive. |
|
Half-life (t½)
|
30 minutes (very short) in adults with normal renal function. ⚠️ Prolonged in renal impairment: up to 4–10 hours in severe CKD / anuria. Prolonged in neonates: 1.5–10 hours (gestational age-dependent — premature neonates have the longest half-life due to immature renal tubular secretion).
|
|
Excretion
|
Primarily renal — approximately 60–90% excreted unchanged in the urine via: (a) glomerular filtration (~10%); (b) active tubular secretion (~50–80% — via OAT1/OAT3 transporters). Small amount (~10%) excreted via biliary route.
|
|
Dialysability
|
✅ YES — removed by haemodialysis. Supplemental dosing post-HD is recommended. Also partially removed by peritoneal dialysis (less efficiently). See RENAL ADJUSTMENT.
|
|
Food effect
|
Not applicable — no oral formulation. |
|
Onset of action
|
IV: Bactericidal activity at the site of infection within minutes of achieving therapeutic serum levels. IM crystalline: 15–30 minutes. IM procaine: 1–4 hours. IM benzathine: 24–48 hours (low peak — suitable only for organisms highly sensitive to very low concentrations, e.g., T. pallidum, Group A Streptococcus).
|
|
Duration of action
|
IV/IM crystalline: 4–6 hours (necessitates frequent dosing — every 4–6 hours). IM procaine: 12–24 hours (allows once- or twice-daily IM dosing). IM benzathine: 3–4 weeks (allows once-monthly dosing for RF prophylaxis; single-dose treatment for early syphilis).
|
| Population | PK Consideration |
|
Elderly (≥60 years)
|
Reduced renal function (age-related GFR decline) → reduced penicillin clearance → prolonged half-life. Dose adjustment based on eGFR is recommended (see RENAL ADJUSTMENT). No specific dose reduction for age alone beyond renal adjustment. |
|
Paediatric
|
Neonates (especially preterm): Markedly prolonged half-life (1.5–10 hours) due to immature renal tubular secretion (OAT1/3 transporters). Half-life decreases progressively with gestational and postnatal age. Term neonates (day 1): t½ ~3 hours; by day 14: ~1.5 hours. Preterm neonates (<32 weeks): t½ ~4–10 hours. Infants and children (>1 month): Clearance per kg is similar to or slightly higher than adults — standard weight-based dosing applies.
|
|
Pregnancy
|
Increased renal blood flow and GFR during pregnancy → increased penicillin clearance → lower serum levels at standard doses. Clinical significance is uncertain for most indications because penicillin has a wide therapeutic index. For syphilis treatment in pregnancy, standard benzathine penicillin doses are considered adequate based on extensive clinical experience (not PK studies). |
|
Obesity
|
Low Vd (0.3–0.4 L/kg) — distributes primarily in extracellular water, not adipose tissue. In significantly obese patients, dosing based on ideal body weight (IBW) is generally appropriate. Actual body weight-based dosing may lead to unnecessarily high doses (though penicillin’s wide therapeutic index provides a large safety margin). For morbidly obese patients with serious infections, clinical judgement applies.
|
|
Renal impairment
|
⚠️ Major impact. 60–90% of benzylpenicillin is eliminated renally. In severe CKD, half-life increases from 30 minutes to 4–10 hours. Dose reduction or interval extension is required. Risk of neurotoxicity (seizures, myoclonus, encephalopathy) increases significantly with drug accumulation in renal failure. See RENAL ADJUSTMENT.
|
|
Critical illness / ICU
|
Altered Vd (third-spacing, oedema, ascites) may transiently increase Vd. Augmented renal clearance (ARC) in young septic patients may increase penicillin clearance → potentially subtherapeutic levels at standard doses. Continuous or extended infusions may be superior to intermittent bolus dosing in critically ill patients — maintains %fT>MIC more reliably. |
|
Hepatic impairment
|
Minimal hepatic metabolism (~10–20%). No dose adjustment required for hepatic impairment alone. |
| Parameter | Crystalline Penicillin (IV/IM) | Procaine Penicillin (IM) | Benzathine Penicillin (IM) |
|
Peak serum concentration
|
High (IV: 20–50 mcg/mL after 2 MU dose; IM: 6–8 mcg/mL)
|
Moderate (1.5–4 mcg/mL after 600,000 IU)
|
Low (0.05–0.15 mcg/mL after 1.2 MU)
|
|
Time to peak
|
IV: immediate; IM: 15–30 min | 1–4 hours | 24–48 hours |
|
Duration above 0.02 mcg/mL (treponemicidal concentration)
|
4–6 hours (per dose) | 12–24 hours | 21–28 days |
|
Adequate for MIC of most streptococci (MIC ~0.01–0.06 mcg/mL)
|
✅ Yes | ✅ Yes | ✅ Yes (low but sufficient for highly susceptible organisms) |
|
Adequate for meningitis (CSF levels needed)
|
✅ Yes (with high IV doses) | ⛔ No (inadequate CSF penetration) | ⛔ No |
|
Adequate for endocarditis (sustained high bactericidal levels needed)
|
✅ Yes (with frequent IV dosing) | ⛔ No (levels too intermittent and low) | ⛔ No |
|
Adequate for syphilis (treponemicidal levels needed)
|
✅ Yes (for neurosyphilis — high IV doses) | ✅ Yes (for early syphilis — IM course) | ✅ Yes (for early syphilis — single IM dose; for late latent — 3 weekly doses) |
| Route | Dose | Frequency | Duration | Clinical Notes |
|
IM (deep intramuscular — gluteal or anterolateral thigh)
|
12 lakh units (1.2 MU) as a single IM injection
|
Every 3 weeks (21 days) — PREFERRED in India. Alternative: every 4 weeks (28 days) — acceptable but slightly inferior in high-risk populations.
|
Duration depends on severity of disease — see below |
⚠️ The 3-weekly interval is strongly recommended in Indian practice (API Textbook, ICMR guidelines, NVHCP protocol) because: (a) the Indian population may metabolise benzathine penicillin slightly faster; (b) tropical climate may increase injection site absorption; © 4-weekly regimens have been associated with breakthrough RF episodes in some Indian studies. The WHO recommends every 4 weeks as acceptable, but Indian expert consensus and ICMR favour every 3 weeks for high-risk patients.
|
| Clinical Scenario | Recommended Duration |
|
RF WITHOUT carditis (no valvular involvement)
|
Minimum 5 years after the last episode of RF, OR until age 21 years — whichever is LONGER.
|
|
RF WITH carditis but NO residual valvular disease (carditis resolved without permanent valve damage)
|
Minimum 10 years after the last episode, OR until age 21 years — whichever is LONGER. Some guidelines recommend until age 25 years.
|
|
RF WITH residual valvular disease (RHD) — mild or moderate
|
Minimum 10 years after the last episode, OR until age 40 years — whichever is LONGER. API Textbook and many Indian cardiologists recommend lifelong prophylaxis.
|
|
Severe RHD (post-valve surgery / valve replacement)
|
⚠️ LIFELONG prophylaxis — recommended by most Indian cardiology centres (AIIMS, PGIMER, CMC Vellore protocols). Recurrent RF can damage even prosthetic valves and worsen residual native valve disease.
|
| Stage | Route | Dose | Frequency | Total Course | Notes |
|
Primary syphilis (chancre)
|
IM
|
24 lakh units (2.4 MU) as a single IM injection
|
SINGLE DOSE
|
One injection only | Divide between two injection sites (12 lakh units per gluteal muscle) for the 2.4 MU dose because of the large volume of suspension. |
|
Secondary syphilis (rash, condylomata, constitutional symptoms)
|
IM
|
24 lakh units (2.4 MU) as a single IM injection
|
SINGLE DOSE
|
One injection only | Same as primary. |
|
Early latent syphilis (<1 year duration)
|
IM
|
24 lakh units (2.4 MU) as a single IM injection
|
SINGLE DOSE
|
One injection only | Same as primary. |
| Stage | Route | Dose | Frequency | Total Course | Notes |
|
Late latent syphilis (>1 year or unknown duration)
|
IM
|
24 lakh units (2.4 MU) per injection
|
Once weekly × 3 weeks (total 3 injections)
|
Total: 72 lakh units (7.2 MU) over 3 weeks
|
⚠️ If a weekly dose is missed by >14 days, the course should be restarted from the beginning. If missed by <14 days, give the dose and continue the schedule. |
|
Tertiary syphilis (cardiovascular, gummatous — non-neurological)
|
IM
|
Same as late latent | Same | Same | Before treating cardiovascular syphilis, rule out neurosyphilis (LP recommended). Aortitis, aortic regurgitation, and coronary ostial stenosis are manifestations — these require concurrent cardiology management alongside antibiotic therapy. |
| Route | Dose | Frequency | Duration | Notes |
|
IV
|
18–24 MU per day (180–240 lakh units/day), administered as 3–4 MU (30–40 lakh units) IV every 4 hours (6 divided doses)
|
Every 4 hours (continuous clock — including overnight doses) |
10–14 days
|
⚠️ Requires inpatient treatment with IV access for the entire duration. Continuous IV infusion of 18–24 MU/day is an acceptable alternative to intermittent bolus dosing. |
| Route | Dose | Frequency | Duration | Notes |
|
IV
|
24 lakh units (2.4 MU) IV every 4 hours (= total 144 lakh units or 14.4 MU per day in 6 divided doses)
|
Every 4 hours (continuous clock) |
7 days (meningococcal meningitis — shorter course than pneumococcal)
|
Some protocols use 4 MU (40 lakh units) every 4 hours (= 24 MU/day) for the initial 48 hours, then reduce to 2.4 MU every 4 hours. Continuous IV infusion is an alternative. |
| Susceptibility | Route | Dose | Frequency | Duration | Combination | Notes |
|
Penicillin MIC ≤0.12 mcg/mL (fully susceptible)
|
IV
|
12–18 MU/day (120–180 lakh units/day) in 6 divided doses (= 2–3 MU every 4 hours)
|
Every 4 hours (continuous clock) |
4 weeks (native valve); 6 weeks (prosthetic valve)
|
± Gentamicin 1 mg/kg IV every 8 hours × first 2 weeks (synergistic regimen — allows shortened course to 2 weeks total in selected cases with native valve IE and no complications)
|
Continuous IV infusion (12–18 MU/day) is an acceptable alternative. |
|
Penicillin MIC 0.12–0.5 mcg/mL (relatively resistant)
|
IV
|
24 MU/day (240 lakh units/day) in 6 divided doses (= 4 MU every 4 hours)
|
Every 4 hours |
4 weeks (native valve); 6 weeks (prosthetic valve)
|
+ Gentamicin 1 mg/kg IV every 8 hours × first 2 weeks
|
Higher penicillin dose needed. |
| Route | Dose | Frequency | Duration | Combination | Notes |
|
IV
|
4 MU (40 lakh units) IV every 4 hours (= 24 MU/day)
|
Every 4 hours |
Until clinical resolution; minimum 10–14 days
|
+ Clindamycin 600–900 mg IV every 8 hours (suppresses toxin production — acts synergistically with penicillin)
|
⚠️ Gas gangrene is a surgical emergency — antibiotic therapy is adjunctive to urgent surgical debridement. Antibiotics WITHOUT surgery are inadequate. Penicillin kills Clostridium perfringens rapidly; clindamycin inhibits toxin synthesis at the ribosomal level.
|
| Severity | Salt Form | Route | Dose | Frequency | Duration | Notes |
|
Severe / Hospitalised CAP (CURB-65 ≥2 or requiring ICU)
|
Crystalline penicillin
|
IV
|
2 MU (20 lakh units) IV every 4–6 hours (= 8–12 MU/day)
|
Every 4–6 hours |
7–10 days (switch to oral amoxicillin when improving — “IV-to-oral switch”)
|
Empirical therapy for hospitalised CAP in India is usually ceftriaxone + azithromycin (covers atypicals and resistant pneumococcus). Switch to IV crystalline penicillin if culture confirms penicillin-susceptible S. pneumoniae (MIC ≤2 mcg/mL for non-meningeal pneumococcal pneumonia — note: higher MIC breakpoint than for meningitis).
|
|
Moderate / Non-severe (CURB-65 0–1, outpatient or step-down)
|
Procaine penicillin
|
IM
|
6–12 lakh units (600,000–1,200,000 IU) IM once daily
|
Once daily |
7 days
|
⚠️ Procaine penicillin IM is IM ONLY. Useful in PHC/CHC settings where IV therapy is not available but the patient needs parenteral antibiotics. Provides sustained levels for 12–24 hours with once-daily dosing. Fortified Procaine Penicillin (FPP) — 4 lakh units IM OD or BD — is commonly used in Indian primary care.
|
| Route | Dose | Frequency | Duration | Notes |
|
IV (preferred for severe/pharyngeal diphtheria)
|
2 MU (20 lakh units) IV every 6 hours (= 8 MU/day)
|
Every 6 hours |
14 days
|
⚠️ Antitoxin (DAT) is the PRIMARY treatment — antibiotics are adjunctive (eradicate the organism and prevent transmission but do NOT neutralise circulating toxin). Administer DAT first, then antibiotics.
|
|
IM (procaine penicillin — if IV not available)
|
6 lakh units (600,000 IU) IM once daily
|
Once daily |
14 days
|
Alternative route for settings without IV access. |
| Route | Dose | Frequency | Duration | Notes |
|
IV (preferred)
|
2 MU (20 lakh units) IV every 6 hours (= 8 MU/day)
|
Every 6 hours |
10–14 days
|
⚠️ Primary treatment is wound debridement + tetanus immunoglobulin (TIG) + supportive care (ICU). Antibiotics eradicate C. tetani from the wound. Metronidazole 500 mg IV every 8 hours is now preferred over penicillin G for tetanus because metronidazole does NOT have the GABA-antagonist activity that penicillin has at high CNS concentrations (theoretical concern: penicillin’s central effects may worsen tetanus spasms). API Textbook and current Indian practice recommend metronidazole as first-line antibiotic for tetanus; penicillin G is an alternative.
|
|
IM (procaine penicillin)
|
6 lakh units (600,000 IU) IM once daily
|
Once daily |
10–14 days
|
Alternative when IV and metronidazole are not available. |
| Route | Dose | Frequency | Duration | Notes |
|
IV
|
1.5 MU (15 lakh units) IV every 6 hours (= 6 MU/day)
|
Every 6 hours |
7 days
|
Standard regimen for severe leptospirosis. Alternative: ceftriaxone 1 g IV OD (equally effective, more convenient). For mild-moderate leptospirosis: doxycycline 100 mg BD oral × 7 days is first-line. |
| Route | Loading Dose | Maintenance | Duration | Notes |
|
IV
|
5 MU (50 lakh units) IV at onset of labour or rupture of membranes
|
2.5–3 MU (25–30 lakh units) IV every 4 hours until delivery
|
Until delivery (discontinue after delivery) |
Drug of choice for intrapartum GBS prophylaxis. Narrower spectrum than ampicillin (the alternative). ℹ️ GBS screening and intrapartum prophylaxis practice in India is less standardised than in Western countries. Universal GBS screening at 35–37 weeks is not routinely performed in most Indian centres. Prophylaxis is given based on risk factors (preterm labour, prolonged ROM >18 hours, intrapartum fever, previous infant with GBS disease, GBS bacteriuria in current pregnancy).
|
| Phase | Route | Dose | Frequency | Duration |
|
Initial (IV phase)
|
IV
|
18–24 MU/day (180–240 lakh units/day) in 6 divided doses
|
Every 4 hours |
2–6 weeks (until clinical improvement)
|
|
Step-down (oral phase)
|
Oral amoxicillin
|
500 mg–1 g TDS | Three times daily |
6–12 months total (prolonged oral therapy is essential to prevent relapse)
|
| Route | Dose | Frequency | Duration | Notes |
|
IV
|
4 MU (40 lakh units) IV every 4 hours (= 24 MU/day)
|
Every 4 hours |
≥14 days (longer if meningitis is present)
|
⚠️ For systemic anthrax (including inhalational): current guidelines recommend ciprofloxacin or doxycycline as the primary agent, with crystalline penicillin (or ampicillin) as an adjunctive second or third agent in the multi-drug regimen. Penicillin monotherapy is inadequate for systemic anthrax (risk of inducible beta-lactamase production by some B. anthracis strains). For cutaneous anthrax (uncomplicated): oral amoxicillin or ciprofloxacin × 7–10 days is standard.
|
| Gestational Age / Postnatal Age | Dose (IV) | Frequency | Notes |
|
Preterm <32 weeks, postnatal age 0–7 days
|
25,000–50,000 units/kg/dose
|
Every 12 hours
|
Lower dose (25,000 units/kg) for sepsis without meningitis; higher dose (50,000 units/kg) for suspected meningitis. |
|
Preterm <32 weeks, postnatal age 8–28 days
|
25,000–50,000 units/kg/dose
|
Every 8 hours
|
Renal maturation allows slightly more frequent dosing. |
|
Preterm 32–36 weeks, postnatal age 0–7 days
|
25,000–50,000 units/kg/dose
|
Every 8 hours
|
|
|
Preterm 32–36 weeks, postnatal age 8–28 days
|
25,000–50,000 units/kg/dose
|
Every 6 hours
|
|
|
Term ≥37 weeks, postnatal age 0–7 days
|
25,000–50,000 units/kg/dose
|
Every 8 hours
|
|
|
Term ≥37 weeks, postnatal age 8–28 days
|
25,000–50,000 units/kg/dose
|
Every 6 hours
|
Approaching standard infant frequency. |
| Scenario | Salt Form | Route | Dose | Frequency | Duration | Notes |
|
Confirmed or highly probable congenital syphilis (abnormal CSF, or physical signs, or reactive non-treponemal test with titre ≥4-fold greater than maternal titre)
|
Crystalline penicillin
|
IV
|
50,000 units/kg/dose
|
Every 12 hours (age 0–7 days); every 8 hours (age 8–28 days)
|
10 days
|
⚠️ IV crystalline penicillin is preferred because it achieves adequate CSF levels (important since neurosyphilis cannot be reliably excluded in neonates).
|
|
Same scenario — when IV not feasible
|
Procaine penicillin
|
IM
|
50,000 units/kg/dose
|
Once daily
|
10 days
|
⚠️ Procaine penicillin does NOT reliably achieve therapeutic CSF levels. If any CNS involvement is suspected, IV crystalline penicillin is mandatory. |
|
Neonatal syphilis — low risk (normal physical exam, normal CSF, reactive non-treponemal test titre NOT ≥4-fold greater than maternal titre, mother adequately treated ≥4 weeks before delivery)
|
Benzathine penicillin
|
IM
|
50,000 units/kg as a SINGLE DOSE
|
Single dose only | Single injection | Alternative approach: some protocols treat all neonates born to syphilis-seropositive mothers with the 10-day regimen rather than risk under-treating. Decision depends on the reliability of maternal treatment documentation and neonatal evaluation. |
| Route | Dose | Frequency | Duration | Notes |
|
IV
|
50,000 units/kg/dose
|
Every 12 hours (preterm) or every 8 hours (term) |
10–14 days
|
⚠️ Metronidazole (7.5 mg/kg IV every 8 hours) is now the preferred antibiotic for neonatal tetanus (see adult tetanus notes — same rationale regarding GABA antagonism). Crystalline penicillin is the alternative if metronidazole is unavailable. Primary treatment: TIG (tetanus immunoglobulin) + supportive ICU care.
|
| Weight | Dose | Frequency | Notes |
|
<27 kg
|
6 lakh units (600,000 IU) IM
|
Every 3 weeks (preferred) or every 4 weeks
|
Inject into anterolateral thigh (children <2 years) or ventrogluteal/dorsogluteal muscle (children ≥2 years). Use 21G needle, 1–1.5 inch length depending on child’s size. |
|
≥27 kg
|
12 lakh units (1.2 MU) IM
|
Every 3 weeks (preferred) or every 4 weeks
|
Adult dose. Inject into gluteal muscle. Divide between two sites if volume is excessive for a single site. |
| Scenario | Salt Form | Route | Dose | Frequency | Duration |
|
Normal CSF
|
Benzathine penicillin
|
IM
|
50,000 units/kg as a single IM dose (max 2.4 MU)
|
Single dose | Single administration |
|
Abnormal CSF or neurological involvement
|
Crystalline penicillin
|
IV
|
50,000 units/kg/dose IV every 4–6 hours
|
Every 4–6 hours |
10–14 days
|
| Route | Dose | Frequency | Duration | Notes |
|
IV
|
50,000 units/kg/dose (some protocols use up to 66,000 units/kg/dose for meningitis)
|
Every 4 hours (= 6 doses/day = 250,000–400,000 units/kg/day)
|
7–10 days (meningococcal); 10–14 days (pneumococcal)
|
Maximum daily dose: 24 MU/day (adult ceiling). ⚠️ Empirical therapy for suspected bacterial meningitis in children in India is ceftriaxone 100 mg/kg/day (max 4 g/day) — NOT crystalline penicillin. Switch to penicillin only if culture confirms penicillin-susceptible organism.
|
| Severity | Salt Form | Route | Dose | Frequency | Maximum | Notes |
|
Severe (hospitalised)
|
Crystalline penicillin
|
IV
|
25,000–50,000 units/kg/dose
|
Every 4–6 hours (= 100,000–300,000 units/kg/day for non-CNS infections)
|
Max 24 MU/day
|
For pneumonia, severe cellulitis, septicaemia with penicillin-susceptible organisms. Step down to oral amoxicillin when clinically improving. |
|
Moderate (IM feasible, IV not available)
|
Procaine penicillin or FPP
|
IM
|
50,000 units/kg/dose (procaine penicillin)
|
Once daily
|
Max 1.2 MU/day
|
⚠️ IM only. Useful in PHC/CHC settings. F-IMNCI (Indian MoHFW protocol) recommends IM procaine penicillin or FPP for severe pneumonia in children when IV access and referral are not immediately available. |
| Route | Dose | Frequency | Duration | Notes |
|
IV
|
25,000–50,000 units/kg/dose
|
Every 6 hours |
14 days
|
⚠️ Antitoxin (DAT) is the PRIMARY treatment. Antibiotics are adjunctive. |
|
IM (procaine penicillin)
|
25,000–50,000 units/kg/dose
|
Once daily |
14 days
|
Alternative when IV not available. |
| Weight | Dose | Route | Frequency | Notes |
|
<27 kg
|
6 lakh units (600,000 IU)
|
IM (single injection)
|
Single dose
|
Ensures complete treatment course in a single visit — no adherence concerns. Recommended by WHO and IAP when compliance with 10-day oral penicillin V course is uncertain (which is common in Indian outpatient settings). |
|
≥27 kg
|
12 lakh units (1.2 MU)
|
IM (single injection)
|
Single dose
|
Adult dose. |
| Route | Dose | Frequency | Duration | Notes |
|
IV
|
25,000–50,000 units/kg/dose
|
Every 6 hours |
7 days
|
Alternative: ceftriaxone 50–80 mg/kg/day IV OD (often preferred for convenience). |
| Scenario | Guidance |
|
Dose delayed by <2 hours
|
Administer as soon as possible. Resume the regular schedule. |
|
Dose delayed by >2 hours
|
Administer immediately. Adjust subsequent doses to maintain the prescribed interval (every 4 hours or every 6 hours) from the time of the delayed dose — do NOT double up. |
|
Dose missed entirely
|
Give the next scheduled dose at the correct time. Do NOT double the dose. Document the missed dose. ⚠️ For serious infections (meningitis, endocarditis), even a single missed dose can result in prolonged sub-MIC periods (due to the short half-life) — this may impair bactericidal activity. Alert the treating physician if doses are missed. |
|
Multiple consecutive doses missed
|
Contact the treating physician immediately. Assess whether the missed doses have compromised treatment efficacy. No re-titration is needed — resume at the same dose. Consider whether continuous IV infusion may provide more reliable drug delivery (especially in ICU settings where nursing handover gaps may cause intermittent dose delays). |
| Scenario | Guidance |
|
Injection delayed by ≤3 days (e.g., due to weekend, holiday, unavailability)
|
Give as soon as possible. Resume the regular 3-weekly or 4-weekly schedule from the date of the delayed injection. |
|
Injection delayed by 4–7 days
|
Give as soon as possible. ⚠️ The patient may have had a period of subtherapeutic penicillin levels. Resume the regular schedule. Monitor for any symptoms of acute RF (fever, joint pain, carditis symptoms) for the next 4–6 weeks. |
|
Injection delayed by >7 days (≥1 week overdue)
|
⚠️ Give the injection immediately. Resume the regular schedule. The patient was likely unprotected for the period of delay. If symptoms of acute RF develop, evaluate and treat accordingly. This is NOT a reason to restart the prophylaxis course — simply resume the schedule.
|
|
Injection missed for ≥1 month (non-adherence)
|
⚠️ Give the injection. Resume the schedule. Counsel the patient/family about the importance of regular injections. If multiple injections have been missed, refer to the treating cardiologist for reassessment (echocardiography to check for new valvular damage). |
| Scenario | Guidance |
|
Weekly dose delayed by <14 days
|
Give the dose and continue the schedule. |
|
Weekly dose delayed by ≥14 days
|
⚠️ Restart the entire 3-dose course from the beginning (per NACO/WHO guidelines). The interruption may have allowed treponemal regrowth, necessitating a complete re-treatment.
|
| Parameter | Details |
|
Supplied as
|
White to off-white crystalline powder in glass vials. Available as 5 lakh units (500,000 IU), 10 lakh units (1 MU), 20 lakh units (2 MU), and 50 lakh units (5 MU) vials. |
|
Diluent for reconstitution
|
Sterile Water for Injection (SWFI) — preferred for reconstitution. 0.9% Sodium Chloride (NS) — also compatible.
|
|
Incompatible diluents
|
⛔ Do NOT reconstitute with dextrose-containing solutions (D5W, D10W) for direct IV push — benzylpenicillin is less stable in dextrose solutions at high concentrations. Dextrose solutions are acceptable for FURTHER DILUTION for IV infusion (see below).
|
|
Reconstitution volumes and concentrations:
|
| Vial Size | Diluent Volume to Add (SWFI or NS) | Approximate Final Concentration | Final Volume |
|
5 lakh units (500,000 IU)
|
1.6 mL | ~250,000 units/mL | ~2 mL |
|
10 lakh units (1 MU)
|
1.6 mL | ~500,000 units/mL | ~2 mL |
| 4 mL | ~200,000 units/mL | ~5 mL | |
|
20 lakh units (2 MU)
|
3.2 mL | ~500,000 units/mL | ~4 mL |
| 8 mL | ~200,000 units/mL | ~10 mL | |
|
50 lakh units (5 MU)
|
8 mL | ~500,000 units/mL | ~10 mL |
| Parameter | Details |
|
Compatible IV fluids
|
0.9% NaCl (Normal Saline) — preferred. 5% Dextrose (D5W) — acceptable for infusion (stability is adequate for the infusion duration if used within 1–2 hours). Ringer’s Lactate — compatible.
|
|
Recommended dilution for intermittent IV infusion
|
Dilute the reconstituted dose in 50–100 mL of NS or D5W for intermittent infusion.
|
|
Recommended dilution for continuous IV infusion
|
Dilute the total daily dose (e.g., 24 MU) in 500–1000 mL of NS and infuse continuously over 24 hours via infusion pump.
|
|
Final concentration range
|
Target: 100,000–500,000 units/mL for IV push; 10,000–50,000 units/mL for intermittent infusion; variable for continuous infusion (based on total daily volume).
|
| Route | Administration Guidance |
|
IV bolus/push
|
Administer slowly over 3–5 minutes per dose (for doses ≤5 MU). For higher single doses (>5 MU), administer over 15–30 minutes as a short infusion to reduce the risk of electrolyte disturbance (sodium/potassium load) and seizures. ⚠️ Very rapid IV push can cause: transient hyperkalaemia (if potassium salt), seizures (especially in renal impairment), and local venous irritation.
|
|
IV intermittent infusion
|
Infuse over 15–30 minutes per dose. Use infusion pump or gravity drip with volume-limiting burette (Soluset) in paediatric patients.
|
|
IV continuous infusion (for endocarditis, meningitis, neurosyphilis — where 100% fT>MIC is desired)
|
Total 24-hour dose in 500–1000 mL NS. Run at a constant rate over 24 hours via infusion pump. Change the infusion bag every 12 hours (stability concern at room temperature — see below). Example: 24 MU/day → prepare 12 MU in 500 mL NS → run at ~21 mL/hr → change bag every 12 hours. |
|
IM injection (crystalline penicillin)
|
Inject deep IM into a large muscle mass (gluteal in adults and older children; anterolateral thigh in infants/young children). Maximum volume per site: 2 mL (adults); 1 mL (infants). Slightly painful due to pH. |
Example: A 12 kg child with suspected meningococcal meningitis. Dose prescribed: 50,000 units/kg/dose IV every 4 hours.
| Condition | Stability |
|
At room temperature (25°C)
|
⚠️ Use within 24 hours of reconstitution. Benzylpenicillin solution degrades progressively at room temperature — loss of potency accelerates above 25°C. In Indian conditions where ambient temperature often exceeds 30°C, use within 6–8 hours if unrefrigerated.
|
|
Under refrigeration (2–8°C)
|
Stable for up to 7 days when refrigerated. However, for clinical safety, use within 48 hours of reconstitution.
|
|
Continuous infusion bags
|
⚠️ Change every 12 hours at room temperature (degradation in solution at 25°C). If refrigerated bags are prepared in advance, allow to warm to room temperature before infusion.
|
|
Light protection
|
Not specifically required, but avoid prolonged exposure to direct sunlight (general good practice). |
| Parameter | Details |
|
Supplied as
|
White powder for suspension in a glass vial. Reconstitute with the diluent provided (usually SWFI) or with 0.9% NaCl. |
|
Diluent volume
|
For 12 lakh unit (1.2 MU) vial: Add approximately 4 mL SWFI. Shake vigorously until a uniform, milky-white suspension is formed. For 24 lakh unit (2.4 MU) vial: Add approximately 6–8 mL SWFI.
|
|
Final appearance
|
Milky-white, opaque suspension. ⚠️ If the suspension is clear or translucent, it is NOT benzathine penicillin — this indicates the wrong salt form has been reconstituted (crystalline penicillin forms a clear solution). This visual check is a critical safety measure.
|
| Parameter | Details |
|
Route
|
⛔ IM ONLY — NEVER IV.
|
|
Needle
|
Use a 21G needle, 1.5 inches (for adults and older children). A smaller gauge (23G) may clog with the viscous suspension. In infants: 23G × 1 inch into anterolateral thigh may be used, but inject very slowly.
|
|
Site
|
Adults and children ≥2 years: ventrogluteal (preferred) or dorsogluteal muscle. Children <2 years: anterolateral thigh (vastus lateralis).
|
|
Technique
|
Draw up the suspension (shake vial immediately before drawing). Aspirate before injection (to confirm NOT in a blood vessel — though aspiration is no longer universally recommended, it remains standard practice for benzathine penicillin to avoid inadvertent IV delivery). Inject slowly over ≥2 minutes (reduces pain and risk of Hoigné reaction). Apply pressure to the site after withdrawal to prevent leakage of the viscous suspension.
|
|
Volume per site
|
Maximum 3–4 mL per injection site in adults; 1–2 mL per site in children. For 2.4 MU dose: divide between two injection sites (e.g., one injection in each buttock).
|
|
Post-injection observation
|
⚠️ Observe the patient for 30 minutes in the clinic/injection room after every benzathine penicillin injection. Have adrenaline (epinephrine) and anaphylaxis kit available.
|
| Compatible (Y-site) | Incompatible — Do NOT Mix |
| Heparin |
⛔ Aminoglycosides (gentamicin, amikacin, tobramycin) — penicillins chemically inactivate aminoglycosides when mixed in the same solution or Y-site. Administer through separate IV lines or flush the line with at least 20 mL NS between penicillin and aminoglycoside.
|
| Potassium chloride (in IV fluid) | Sodium bicarbonate (alkaline solutions accelerate penicillin hydrolysis) |
| Hydrocortisone (some compatibility data) | Metronidazole (limited compatibility data — avoid mixing) |
| Ranitidine | Amphotericin B |
| Normal saline flush | Blood products — do NOT administer through the same line as blood |
| Parameter | Details |
|
Filter requirements
|
No specific in-line filter required for IV crystalline penicillin. |
|
Flush line
|
Flush with 5–10 mL NS before and after IV administration (especially if alternating with aminoglycosides in the same line). |
|
Extravasation risk
|
LOW — crystalline penicillin is NOT a vesicant. However, concentrated solutions are irritant to peripheral veins and may cause phlebitis with prolonged peripheral IV administration. Consider central line for courses >3–5 days at high doses (endocarditis, neurosyphilis). |
|
IM injection notes (crystalline)
|
Painful injection. Rotate sites. Maximum 2 mL per site. |
|
Enteral tube
|
Not applicable — no oral formulation. |
| Formulation | Storage |
| Crystalline penicillin (unopened powder vial) | Room temperature, below 30°C, protect from moisture. |
| Crystalline penicillin (reconstituted) | Use immediately if possible. If stored: refrigerate (2–8°C), use within 24–48 hours. |
| Benzathine penicillin (unopened powder vial) | Room temperature, below 30°C, protect from moisture. |
| Benzathine penicillin (reconstituted suspension) |
Use immediately after reconstitution. Do NOT store reconstituted suspension.
|
| Procaine penicillin (unopened powder/suspension) | Room temperature, below 30°C, protect from moisture. |
| Procaine penicillin (reconstituted suspension) |
Use immediately.
|
| eGFR (mL/min) | Dose Adjustment | Notes |
|
>60
|
No adjustment required. Standard dosing applies. | Full doses for all indications. |
|
30–60
|
No routine adjustment for standard doses (≤12 MU/day). For high-dose regimens (>12 MU/day — meningitis, endocarditis): Consider reducing daily dose by 25% OR extending the dosing interval from every 4 hours to every 6 hours.
|
Monitor for neurotoxicity (myoclonus, seizures). |
|
15–30
|
⚠️ Reduce dose by 25–50% OR extend dosing interval to every 6–8 hours. For high-dose regimens: use maximum 50–75% of the standard daily dose.
|
⚠️ Significant accumulation risk. Monitor closely for neurotoxicity. Check electrolytes (sodium load from the sodium salt; potassium load from the potassium salt). |
|
<15 (non-dialysis)
|
⚠️ Reduce dose to 25–50% of standard AND extend interval to every 8–12 hours. For endocarditis/meningitis (where adequate drug levels are essential): specialist input required — balance neurotoxicity risk against need for therapeutic efficacy.
|
⚠️ High risk of neurotoxicity and electrolyte disturbance. Monitor serum creatinine, electrolytes (Na⁺, K⁺), and neurological status (myoclonus, seizures) daily. |
|
Haemodialysis
|
✅ Benzylpenicillin IS removed by haemodialysis. Give a supplemental dose after each HD session — typically 50–75% of the standard dose post-dialysis.
|
Schedule the main dose to follow HD sessions. On non-dialysis days, use the dose/interval appropriate for eGFR <15. |
|
Peritoneal dialysis
|
Partially removed by PD (less efficiently than HD). Use doses appropriate for eGFR <15. No specific post-PD supplemental dose is standard, but monitor clinical response and adjust.
|
Limited formal data. |
|
CRRT
|
Drug clearance is increased compared to intermittent HD. Use 50–75% of the standard dose with standard dosing intervals (every 4–6 hours). Adjust based on clinical response and institutional CRRT protocol.
|
Consider continuous infusion for optimal drug delivery during CRRT. |
| eGFR | Adjustment | Notes |
|
All levels
|
No dose adjustment required.
|
Benzathine penicillin IM achieves very low peak serum levels (0.05–0.15 mcg/mL) — well below the threshold for neurotoxicity. Renal impairment prolongs the already-long duration of action (which is actually beneficial for prophylaxis). The risk of toxicity is negligible. |
| eGFR | Adjustment | Notes |
|
>30
|
No adjustment required. | |
|
15–30
|
Use with caution. Consider reducing frequency to alternate-day dosing if a multi-day course is needed. | Monitor for procaine toxicity (CNS excitation, seizures) in addition to penicillin accumulation. |
|
<15
|
⚠️ Avoid if possible. If no alternative, use alternate-day dosing with monitoring. Prefer IV crystalline penicillin (with renal dose adjustment) when feasible. |
| Child-Pugh Class | Adjustment | Notes |
|
A (Mild)
|
No adjustment required. | |
|
B (Moderate)
|
No adjustment required. | |
|
C (Severe)
|
No adjustment required. | ℹ️ Even in severe cirrhosis, the primary route of elimination (renal) is unaffected by hepatic impairment alone. If hepatorenal syndrome is present (concurrent renal impairment), adjust for the renal impairment component — see RENAL ADJUSTMENT. |
| Contraindication | Clinical Rationale |
|
⛔ Known IgE-mediated (Type I) hypersensitivity to any penicillin
|
Risk of anaphylaxis — a life-threatening emergency (bronchospasm, laryngeal oedema, hypotension, cardiovascular collapse, death). IgE-mediated reactions occur within minutes to 1 hour of penicillin administration. History of any of the following to any penicillin constitutes an absolute contraindication: anaphylaxis, angioedema, urticaria within 1 hour of administration, bronchospasm, hypotension. ⚠️ A history of a non-specific “rash” to penicillin in childhood (common parental report in India) does NOT automatically constitute a contraindication — most such rashes are viral exanthems or non-IgE-mediated reactions, and the patient may be safely re-challenged after proper allergy assessment. However, in the absence of formal allergy testing, err on the side of caution in routine practice. Formal penicillin allergy testing (skin prick test + intradermal test) is available at select Indian tertiary centres (AIIMS, PGI, CMC Vellore, select private allergy centres) and should be considered before labelling a patient as “penicillin-allergic” for life — because this label excludes them from the most effective treatments for RF prophylaxis, syphilis, and endocarditis.
|
|
⛔ IV administration of procaine benzylpenicillin or benzathine benzylpenicillin
|
⛔ FATAL. These depot formulations are suspensions (not solutions). IV injection causes embolic phenomena: pulmonary microembolism, coronary occlusion → cardiac arrest and death. Also causes Hoigné reaction (procaine) — acute psychomotor agitation, fear of death, seizures. These formulations are IM ONLY. This is NOT a drug allergy contraindication — it is a ROUTE contraindication.
|
|
⛔ Intrathecal administration of any benzylpenicillin formulation
|
⛔ Intrathecal injection of penicillin causes severe neurotoxicity — seizures, encephalopathy, arachnoiditis, death. Penicillin is a known GABA-A receptor antagonist at high CNS concentrations. Intrathecal injection achieves extremely high local CNS concentrations far exceeding the neurotoxicity threshold. NEVER administer by intrathecal or intraventricular route.
|
| Drug/Class | Cross-Reactivity with Penicillins | Approximate Rate | Nature | Clinical Action |
|
Other penicillins (amoxicillin, ampicillin, cloxacillin, piperacillin)
|
⛔ YES — very high
|
~100% (shared core beta-lactam + thiazolidine ring → identical major antigenic determinant) | Structure-based (predictable) |
⛔ All penicillins are contraindicated if there is confirmed IgE-mediated allergy to any penicillin.
|
|
Cephalosporins (1st generation) (cephalexin, cefazolin)
|
YES — moderate
|
~1–2% cross-reactivity with current estimates (earlier estimates of 5–10% were based on methodologically flawed studies with impure cephalosporin preparations). First-generation cephalosporins have the highest structural similarity to penicillins (similar R1 side chain).
|
Structure-based (R1 side chain similarity) |
⚠️ Avoid first-generation cephalosporins in patients with confirmed severe (anaphylactic) penicillin allergy. May be used with caution (supervised first-dose in a monitored setting) in patients with non-severe penicillin allergy (non-urticarial rash, remote history).
|
|
Cephalosporins (2nd–4th generation) (cefuroxime, ceftriaxone, cefotaxime, cefepime)
|
LOW
|
<0.5–1% cross-reactivity
|
Less structural similarity (different R1 side chains) |
ℹ️ Generally considered safe to use in patients with penicillin allergy (including anaphylaxis) — BUT administer the first dose under observation (monitored setting with anaphylaxis kit available) in patients with a history of penicillin anaphylaxis. Ceftriaxone is the most commonly used alternative in Indian practice when penicillin allergy precludes penicillin use (e.g., meningitis, syphilis alternatives).
|
|
Carbapenems (meropenem, imipenem, ertapenem)
|
VERY LOW
|
<1% cross-reactivity
|
Different ring structure (carbapenem vs penam) | ℹ️ Safe to use in penicillin-allergic patients. First dose under observation in anaphylaxis history. |
|
Monobactams (aztreonam)
|
NONE (no cross-reactivity)
|
0% | Completely different ring structure (monocyclic) |
✅ Safe in penicillin-allergic patients — no cross-reactivity. However, aztreonam has very limited availability and clinical use in India.
|
|
Aminopenicillins with side chain similarity to specific cephalosporins (amoxicillin ↔ cephalexin/cefadroxil)
|
HIGHER within these specific pairs
|
~2–4% | Identical R1 side chain in specific pairs | ⚠️ If allergy is specifically to amoxicillin (not penicillin G), cephalexin and cefadroxil carry a slightly higher cross-reactivity risk than other cephalosporins. |
| Condition | Risk | Required Monitoring / Action |
|
⚠️ Renal impairment (eGFR <30 mL/min)
|
⚠️ Penicillin neurotoxicity — the most important clinical risk of high-dose crystalline penicillin in renal failure. Presents as: myoclonus (early sign), generalised tonic-clonic seizures, encephalopathy (confusion, obtundation), hallucinations. Mechanism: accumulation of benzylpenicillin → high CNS concentrations → GABA-A receptor antagonism → neuronal excitotoxicity. Risk is proportional to dose and inversely proportional to renal function.
|
⚠️ Mandatory dose reduction — see RENAL ADJUSTMENT. Monitor neurological status daily (myoclonus is the earliest sign — ask about and examine for involuntary muscle jerking, especially in the face and extremities). If myoclonus or seizures develop: reduce dose immediately or stop; benzodiazepines for acute seizures (diazepam 5–10 mg IV or midazolam 2–5 mg IV). Check serum creatinine and electrolytes. Consider haemodialysis for severe toxicity.
|
|
⚠️ Electrolyte disturbance — sodium and potassium load at high doses
|
Each 1 MU (10 lakh units) of benzylpenicillin sodium contains ~1.7 mEq Na⁺. At 24 MU/day = ~41 mEq Na⁺/day (significant sodium load in heart failure, renal failure, or fluid-restricted patients). Benzylpenicillin potassium salt (less common in India): each 1 MU contains ~1.7 mEq K⁺. At 24 MU/day = ~41 mEq K⁺/day → ⚠️ risk of hyperkalaemia, especially in renal impairment, concurrent potassium-sparing diuretics, ACE inhibitors, or ARBs.
|
Monitor serum electrolytes (Na⁺, K⁺) daily at high doses (>12 MU/day). Preferentially use the sodium salt (standard in India) to avoid hyperkalaemia risk. If the potassium salt is supplied, verify with pharmacy and monitor K⁺ closely. In fluid-restricted patients (heart failure, renal failure), account for the sodium load in the daily fluid/electrolyte plan.
|
|
⚠️ History of seizure disorder or CNS lesion
|
Penicillin is a known proconvulsant (GABA-A antagonist at high CNS concentrations). Patients with pre-existing epilepsy, structural brain lesions, or prior CNS surgery have a lower seizure threshold. Risk is significantly amplified in the presence of concurrent renal impairment (drug accumulation → higher CNS levels). | Use the lowest effective dose compatible with the clinical indication. Ensure antiepileptic medications are continued. Monitor for new-onset seizures. Have benzodiazepines available. |
|
⚠️ Concurrent aminoglycoside therapy (neonatal sepsis, endocarditis)
|
Physical incompatibility — penicillins chemically inactivate aminoglycosides when mixed in the same IV line or solution. This can result in subtherapeutic aminoglycoside levels → treatment failure. Also: both drugs are nephrotoxic at high doses (penicillin — interstitial nephritis; aminoglycoside — tubular toxicity).
|
⛔ NEVER mix in the same IV line, syringe, or infusion bag. Flush the line with ≥20 mL NS between penicillin and aminoglycoside administration. Use separate IV sites if possible. Monitor renal function and aminoglycoside levels (TDM) when used together.
|
|
⚠️ Hoigné reaction risk (benzathine and procaine penicillin IM)
|
Non-allergic pseudo-anaphylactic reaction occurring within seconds to minutes of IM injection of depot penicillin formulations. Presents with acute fear of death, visual and auditory disturbances, agitation, bizarre behaviour, tachycardia, sometimes seizures. Mechanism: microembolisation of depot suspension into small vessels → transient CNS effects (procaine component also contributes direct CNS excitation). NOT an IgE-mediated allergic reaction. | Distinguish from true anaphylaxis: Hoigné reaction does NOT include urticaria, angioedema, bronchospasm, or hypotension. Management: supportive — reassurance, calm environment, benzodiazepine (diazepam 5–10 mg IV or midazolam 2 mg IM) for severe agitation or seizures. Resolves spontaneously within 15–30 minutes. Does NOT contraindicate future penicillin injections (though the patient may refuse). |
|
⚠️ Jarisch-Herxheimer reaction (syphilis treatment)
|
Occurs in 10–35% of patients treated for early syphilis. Onset 2–8 hours after first penicillin dose. Fever, rigors, headache, myalgia, hypotension (rarely), worsening of rash. Due to treponemal endotoxin-like lipoprotein release from dying organisms. In pregnant women: can cause uterine contractions, fetal distress, preterm labour. | Counsel the patient before treatment. Manage with paracetamol and fluids. Does NOT require discontinuation of penicillin. In pregnant women: administer penicillin under obstetric monitoring (CTG available). Consider premedication with prednisolone in late pregnancy (some protocols recommend prednisolone 40 mg daily for 3 days starting 24 hours before penicillin — evidence is limited but practice-based). |
| Condition | Notes |
|
Non-severe penicillin allergy history (delayed rash, GI upset)
|
Non-IgE-mediated reactions (maculopapular rash appearing >1 hour after administration, GI disturbance) do NOT constitute absolute contraindications but warrant documentation and awareness. May proceed with caution (first dose in a monitored setting with anaphylaxis kit available). Consider penicillin skin testing if the indication is long-term (RF prophylaxis). |
|
Cystic fibrosis
|
Patients with CF have altered pharmacokinetics of many antibiotics (including penicillins) — increased Vd and increased renal clearance. Standard doses may be subtherapeutic. Higher doses and/or more frequent dosing may be needed — specialist input required. |
|
Mononucleosis (Epstein-Barr virus infection)
|
⚠️ Ampicillin/amoxicillin cause a characteristic maculopapular rash in nearly 100% of mononucleosis patients. Benzylpenicillin (penicillin G) is LESS commonly associated with this rash than aminopenicillins, but the risk is not zero. If penicillin G is needed in a patient with EBV infection (uncommon scenario), monitor for rash. This is NOT an IgE-mediated allergy — it is a virus-drug interaction. |
|
Heart failure / fluid overload
|
The sodium content of high-dose crystalline penicillin sodium (~41 mEq Na⁺/day at 24 MU/day) may exacerbate fluid retention. Account for sodium load in the daily fluid and electrolyte plan. |
|
Patients on warfarin or other anticoagulants
|
High-dose IV penicillin can rarely cause coagulopathy (platelet dysfunction, interference with vitamin K-dependent clotting factors). Monitor INR more frequently if warfarin is co-prescribed. Clinically significant bleeding is rare. |
|
Patients with implanted prosthetic devices receiving benzathine penicillin IM
|
Some older guidelines expressed theoretical concern about haematogenous seeding of prosthetic joints or valves from IM injection site bacteraemia. This concern is not supported by clinical evidence. Benzathine penicillin IM for RF prophylaxis should NOT be withheld from patients with prosthetic heart valves — they are among the highest-risk group for RF recurrence and NEED prophylaxis the most. |
|
G6PD deficiency
|
No significant haemolytic risk with penicillins. Safe to use. |
|
Prolonged courses (>2 weeks)
|
Monitor for Coombs-positive haemolytic anaemia (rare — reported with high-dose prolonged courses), interstitial nephritis (fever, rash, eosinophilia, rising creatinine), and superinfection (oral/vaginal candidiasis, C. difficile colitis).
|
| Parameter | Details |
|
Overall safety statement
|
✅ Safe in pregnancy — all trimesters. Benzylpenicillin (all salt forms) is one of the safest antibiotics in pregnancy. Extensive human experience over >75 years with no confirmed teratogenicity. Crosses the placenta but no adverse fetal effects at therapeutic doses. (Former US-FDA Category B — animal studies showed no harm; extensive human experience confirms safety.)
|
|
Teratogenicity window
|
No teratogenic risk at any gestational age. Safe throughout pregnancy including the critical organogenesis period (weeks 3–8 post-conception). |
|
Trimester-specific risks
|
First trimester: No increased malformation risk. Safe. Second trimester: Safe. Third trimester: Safe. ⚠️ Jarisch-Herxheimer reaction in late pregnancy (when treating syphilis) can trigger uterine contractions, fetal distress, and preterm labour — administer under obstetric monitoring.
|
|
Specific indications in pregnancy
|
(a) Syphilis treatment in pregnancy — benzathine penicillin is the ONLY recommended treatment. No alternative is considered adequate for preventing congenital syphilis. ⛔ Doxycycline is contraindicated in pregnancy (fetal teeth/bone effects). ⛔ Azithromycin does NOT reliably cross the placenta to treat fetal infection. If the patient is penicillin-allergic: penicillin desensitisation is mandatory — then treat with penicillin. (b) RF prophylaxis — must NOT be interrupted during pregnancy. Continue benzathine penicillin IM every 3 weeks throughout pregnancy. © GBS intrapartum prophylaxis — crystalline penicillin IV during labour. (d) Any bacterial infection requiring penicillin — safe to use.
|
|
Preferred alternatives in pregnancy
|
No alternative is needed — benzylpenicillin is itself one of the safest antibiotics in pregnancy. If penicillin allergy precludes use: cephalosporins (cefazolin, ceftriaxone — with appropriate allergy cross-reactivity precautions), erythromycin, or azithromycin, depending on the specific infection. |
|
What to monitor (mother)
|
Standard infection monitoring. For syphilis treatment: monitor for JHR (2–8 hours post-injection), uterine contractions, and fetal heart rate. |
|
What to monitor (fetus)
|
For syphilis treatment in pregnancy: CTG monitoring during and after the first injection (JHR risk). Routine antenatal monitoring otherwise. |
|
Pre-conception counselling
|
Not applicable — no pre-conception concerns with penicillin. |
|
Contraception requirement
|
Not required. |
| Parameter | Details |
|
Compatibility with breastfeeding
|
✅ Compatible — safe during breastfeeding. Benzylpenicillin is excreted into breast milk in very small quantities. The relative infant dose (RID) is estimated at <1% of the maternal weight-adjusted dose — well within the safe range (<10%). The drug is poorly absorbed orally by the infant (acid-labile — destroyed in the infant’s stomach), further reducing effective infant exposure. Penicillins are among the safest antibiotics during lactation.
|
|
Drug levels in milk
|
Very low. Milk:plasma ratio is approximately 0.02–0.13 (very little drug transfers into milk). Combined with the infant’s poor oral absorption of benzylpenicillin, net infant exposure is negligible.
|
|
What to monitor in infant
|
Routine monitoring only. Theoretical concerns: (a) alteration of infant gut flora (may cause mild diarrhoea or oral thrush — very rare at the negligible exposure levels); (b) sensitisation to penicillin (theoretical — no clinical evidence that breast milk penicillin exposure causes later penicillin allergy). |
|
Preferred alternatives during lactation
|
Not needed — benzylpenicillin is itself safe during lactation. |
|
Timing advice
|
Not required — the drug is compatible with breastfeeding without timing restrictions. |
| Parameter | Details |
|
Recommended starting dose
|
Same as adult dosing for most indications — benzylpenicillin does not require age-based dose reduction per se. However, dose adjustment for renal function (which declines with age) is the primary consideration. Estimate eGFR in all elderly patients before initiating high-dose crystalline penicillin. In an elderly patient with eGFR 30–60 mL/min receiving high-dose therapy: reduce dose or extend interval as per RENAL ADJUSTMENT table.
|
|
Titration
|
Not applicable — penicillin dosing is weight/indication-based, not titrated. |
|
Key risks in elderly
|
1. Renal function decline — the most important consideration. Age-related GFR decline (even without overt CKD) reduces penicillin clearance. A serum creatinine that appears “normal” in an elderly patient may mask a significantly reduced eGFR (due to lower muscle mass and creatinine generation). Always calculate eGFR — do not rely on serum creatinine alone. 2. Penicillin neurotoxicity — risk is amplified in elderly patients with renal impairment receiving high-dose IV crystalline penicillin. The ageing brain has reduced seizure threshold, and the combination of drug accumulation + CNS vulnerability makes elderly patients the highest-risk group for penicillin-induced seizures and encephalopathy. 3. IM injection challenges — elderly patients with sarcopenia (reduced muscle mass) may have less ideal IM injection sites for benzathine penicillin (gluteal muscle wasting). Consider the ventrogluteal site (better muscle bulk even in sarcopenic patients). Ensure adequate needle length to reach muscle (subcutaneous injection of benzathine penicillin is ineffective and may cause sterile abscess). 4. Phlebitis from IV crystalline penicillin — elderly patients with fragile peripheral veins are more susceptible to irritant phlebitis from concentrated penicillin solutions. Consider early placement of a PICC line or central line for courses >3 days. 5. Hypersensitivity — elderly patients may have been exposed to penicillin many times over their lifetime, potentially with undocumented allergic events. Take a thorough allergy history. 6. Superinfection — elderly patients (especially those on concurrent acid-suppressing drugs, immunocompromised, or hospitalised) are at higher risk of Clostridioides difficile infection during antibiotic therapy. Monitor stool frequency and character.
|
| Scenario | Guidance |
|
Elderly patient with RHD on lifelong benzathine penicillin prophylaxis
|
ℹ️ Current Indian guidelines recommend lifelong prophylaxis for patients with significant RHD (especially those with prosthetic valves or severe valvular disease). However, in elderly patients (>60 years) with stable mild RHD who have had no RF recurrence for >10 years, some cardiologists consider individualised discontinuation after shared decision-making. The risk of GAS pharyngitis (the trigger for RF) declines with age, and the risk-benefit of monthly injections may shift. There is no formal consensus on this — discuss with the treating cardiologist.
|
|
Elderly patient completing an antibiotic course
|
Standard antibiotic stewardship — stop at the prescribed duration. No tapering needed. |
| Interacting Drug/Substance | Mechanism | Clinical Effect | Onset Type | Action Required |
|
⛔ Aminoglycosides — physical incompatibility in IV solution (gentamicin, amikacin, tobramycin, streptomycin)
|
Chemical inactivation — the beta-lactam ring of penicillin nucleophilically attacks the amino groups of aminoglycosides, forming inactive amide bonds. This occurs when the two drugs are mixed in the same solution or run through the same IV line without flushing. |
⚠️ Inactivation of the aminoglycoside → subtherapeutic aminoglycoside levels → treatment failure. The penicillin is also partially consumed but remains effective (it is present in much higher molar concentration). ℹ️ This is a physical/chemical incompatibility, NOT a pharmacological interaction. When given separately (different IV lines or with adequate flushing), the two drugs act synergistically against streptococci and enterococci — this synergy is the basis of combination therapy in endocarditis and neonatal sepsis.
|
Immediate — inactivation occurs within minutes of mixing
|
⛔ NEVER mix in the same IV bag, syringe, or Y-site without flushing. Administer through separate IV lines, OR flush the line with ≥20 mL NS between penicillin and aminoglycoside. In neonatal sepsis (penicillin + gentamicin protocol): give penicillin first, flush, then give gentamicin through the same line. If two IV sites are available, use separate sites. ℹ️ The synergistic pharmacodynamic effect is preserved when the drugs are given separately — only the physical mixing is contraindicated.
|
|
⚠️ Methotrexate
|
Benzylpenicillin (and other penicillins) competes with methotrexate for renal tubular secretion via OAT1/OAT3 transporters. This reduces methotrexate clearance and increases methotrexate plasma levels.
|
⚠️ Increased methotrexate toxicity — myelosuppression (pancytopaenia), mucositis, nephrotoxicity, hepatotoxicity. Particularly dangerous with high-dose methotrexate regimens (oncology).
|
Gradual onset — over 24–72 hours as methotrexate accumulates
|
⚠️ Avoid concurrent use of high-dose penicillin with high-dose methotrexate. If unavoidable (e.g., treating infection during methotrexate therapy): monitor methotrexate levels closely, monitor renal function, and monitor for methotrexate toxicity. Low-dose methotrexate (rheumatology — 7.5–25 mg/week) is less risky but still warrants monitoring.
|
|
⚠️ Warfarin and other vitamin K antagonists
|
(a) High-dose IV penicillin may inhibit platelet aggregation and suppress vitamin K-producing gut flora → additive anticoagulant effect. (b) Large-volume IV penicillin sodium infusions increase sodium and fluid load, potentially affecting warfarin distribution. |
⚠️ Increased INR / bleeding risk — usually modest and clinically significant only at high penicillin doses (>12 MU/day) or prolonged courses.
|
Gradual onset — over days
|
⚠️ Monitor INR more frequently (every 2–3 days) when high-dose IV penicillin is co-administered with warfarin. Adjust warfarin dose as needed. Risk is LOW with benzathine penicillin IM (low systemic levels).
|
|
⚠️ Live vaccines (oral typhoid [Ty21a], BCG, oral polio)
|
Antibiotics may reduce the viability of live vaccine organisms during concurrent administration. Benzylpenicillin has activity against some organisms used in live vaccines. |
⚠️ Potentially reduced vaccine efficacy. Primarily relevant for oral typhoid vaccine (Ty21a) — which is a live Salmonella typhi strain susceptible to penicillins.
|
Acute onset
|
⚠️ Complete the antibiotic course before administering oral typhoid vaccine — wait at least 3 days after the last penicillin dose. Injectable typhoid vaccine (Vi polysaccharide — Typhim Vi) is NOT affected (inactivated vaccine). BCG and OPV are less likely to be affected but separate by 3 days if possible.
|
| Interacting Drug/Substance | Mechanism | Clinical Effect | Onset Type | Action Required |
|
Probenecid
|
Probenecid inhibits OAT1/OAT3-mediated renal tubular secretion of benzylpenicillin → reduced renal clearance → increased penicillin serum levels (approximately 2-fold increase in AUC) and prolonged half-life (from ~30 min to ~60–90 min).
|
Increased penicillin levels — this is a therapeutically BENEFICIAL interaction that was historically exploited to enhance penicillin efficacy before high-dose formulations were available. Currently used in the procaine penicillin + probenecid regimen for neurosyphilis (when IV crystalline penicillin is not feasible).
|
Acute onset — effect begins within 1–2 hours of probenecid administration
|
ℹ️ Intentional use: In the neurosyphilis regimen (procaine penicillin 2.4 MU IM daily + probenecid 500 mg QID × 10–14 days), this interaction is deliberately exploited to raise serum and CSF penicillin levels. Probenecid adherence is critical — missed probenecid doses render the regimen subtherapeutic. ℹ️ Unintentional co-prescribing: If a patient is already on probenecid for gout and receives penicillin, expect higher penicillin levels. Usually beneficial but may require penicillin dose reduction in renal impairment to avoid neurotoxicity from excessive accumulation.
|
|
Tetracyclines (doxycycline, tetracycline) and Chloramphenicol
|
Bacteriostatic antibiotics (tetracyclines, chloramphenicol) may theoretically antagonise the bactericidal action of penicillin. Penicillin requires actively dividing bacteria to exert its cell-wall-synthesis-inhibiting action; bacteriostatic drugs halt bacterial division. |
Theoretical reduced bactericidal efficacy of penicillin. ℹ️ Clinical significance is debated — early in-vitro and animal studies demonstrated antagonism, but clinical evidence of treatment failure from this combination is limited. Modern infectious disease practice generally avoids concurrent use when possible but does not consider it absolutely contraindicated.
|
Acute onset (pharmacodynamic)
|
ℹ️ Avoid concurrent use when possible — use one or the other, not both. If both are genuinely needed (rare clinical scenario), administer penicillin first and tetracycline later (allow initial bactericidal killing before bacteriostasis). In practice, this interaction is rarely clinically relevant because penicillin and tetracyclines cover different organisms and are rarely co-prescribed for the same infection.
|
|
Oral contraceptives (combined OCP)
|
ℹ️ Historical concern — now largely DEBUNKED. Old teaching suggested that antibiotics (including penicillins) reduce OCP efficacy by disrupting gut flora that hydrolyse oestrogen conjugates → reduced enterohepatic circulation of ethinyl oestradiol → reduced OCP efficacy → contraceptive failure.
|
Current evidence: Large pharmacokinetic studies and population studies have found NO clinically significant reduction in OCP efficacy with penicillin co-administration. The only antibiotic confirmed to reduce OCP efficacy is rifampicin (a potent CYP3A4 inducer — different mechanism).
|
— |
ℹ️ No additional contraception is needed when taking penicillin with combined OCPs. This is a common myth in Indian practice — many prescribers still advise “use barrier contraception while on antibiotics.” Current evidence does NOT support this advice for penicillins.
|
|
NSAIDs (indomethacin, ibuprofen, diclofenac)
|
NSAIDs may compete with penicillin for OAT-mediated renal tubular secretion → slightly increased penicillin levels. NSAIDs also reduce renal blood flow → decreased penicillin clearance. |
Modestly increased penicillin levels. Usually clinically insignificant at standard penicillin doses. Potentially relevant at very high penicillin doses in patients with pre-existing renal impairment.
|
Gradual onset
|
ℹ️ No dose adjustment needed in most cases. Be aware of the interaction in patients receiving both high-dose penicillin AND NSAIDs with pre-existing renal impairment — monitor for penicillin neurotoxicity. |
|
Potassium-sparing diuretics, ACE inhibitors, ARBs (when benzylpenicillin POTASSIUM salt is used)
|
Additive hyperkalaemia risk — potassium salt of benzylpenicillin provides ~1.7 mEq K⁺ per 1 MU. Combined with K⁺-retaining drugs, total potassium load may cause clinically significant hyperkalaemia. |
⚠️ Hyperkalaemia — especially at high penicillin doses (>12 MU/day of the potassium salt).
|
Gradual onset (over days of high-dose treatment)
|
⚠️ Preferentially use benzylpenicillin SODIUM salt (standard in India). If potassium salt is used: monitor serum K⁺ daily. Avoid concurrent potassium supplements. Alert the prescribing team to the potassium content of each vial.
|
|
Cholestyramine / other bile acid sequestrants
|
Not applicable — benzylpenicillin is parenteral only (no oral absorption to interfere with). | None | — | Not applicable. |
| Adverse Effect | System | Notes |
|
Injection site pain (IM — especially benzathine and procaine penicillin)
|
Local / Musculoskeletal |
The most frequently reported adverse effect across all injectable penicillin formulations. Benzathine penicillin IM is particularly painful due to the viscous suspension and large volume. Pain at injection site is reported in virtually all patients (incidence approaches 100% for benzathine penicillin IM). This is the single biggest barrier to adherence for RF prophylaxis in India, particularly in children. Strategies to reduce pain: EMLA cream 60 minutes before injection, use 21G needle (not smaller — smaller gauges increase injection time), warm the vial to room temperature, inject slowly over ≥2 minutes, Z-track technique, lidocaine diluent reconstitution (see below). ℹ️ Lidocaine as diluent: Some Indian protocols reconstitute benzathine penicillin with 1% lidocaine instead of SWFI to reduce injection pain. This practice is common in paediatric rheumatology clinics. Evidence supports modest pain reduction. ⚠️ Ensure the patient has no lidocaine allergy before using this technique. Do NOT use lidocaine with adrenaline (epinephrine) as diluent.
|
|
Injection site induration / hardness (IM — depot formulations)
|
Local | Palpable lump at the injection site lasting days to weeks after benzathine or procaine penicillin IM. Due to the slow dissolution of the depot suspension. Usually painless after the initial 24–48 hours. Does NOT indicate infection or abscess unless accompanied by increasing pain, warmth, erythema, or purulent discharge. Advise the patient that a “lump” is expected. |
| Adverse Effect | System | Notes |
|
Diarrhoea
|
GI |
Due to disruption of normal gut flora. Usually mild and self-limiting. More common with prolonged courses (>7 days) and high doses. Monitor for C. difficile infection if diarrhoea is severe, bloody, or persistent.
|
|
Nausea
|
GI | Mild. More common with IV administration (may be related to rate of infusion). Usually transient. |
|
Maculopapular rash (non-urticarial, delayed)
|
Dermatological / Immunological |
Occurs in approximately 2–5% of patients. Onset typically >72 hours after starting penicillin (delayed — Type IV hypersensitivity). Non-pruritic or mildly pruritic maculopapular eruption on trunk and extremities. ⚠️ This is a non-IgE-mediated reaction and does NOT indicate risk of future anaphylaxis. However, it is often misclassified as “penicillin allergy” in Indian medical records, resulting in lifelong avoidance of all penicillins — a significant problem for patients who later need penicillin for RF prophylaxis or syphilis. ℹ️ A delayed maculopapular rash should be documented as “non-severe delayed rash — NOT anaphylactic allergy” to avoid inappropriate penicillin avoidance in the future. Formal allergy assessment (skin testing) can clarify the situation.
|
|
Oral / vaginal candidiasis (thrush)
|
Infectious |
Due to suppression of normal bacterial flora allowing Candida overgrowth. More common with prolonged courses and broad-spectrum penicillins (aminopenicillins > penicillin G). Benzylpenicillin’s narrow spectrum makes this less common than with amoxicillin/ampicillin, but it still occurs. Treat with topical antifungals (clotrimazole, nystatin).
|
|
Phlebitis / thrombophlebitis (IV site)
|
Local / Vascular | Occurs in approximately 5–10% of patients receiving IV crystalline penicillin via peripheral cannula. Due to the alkaline pH of reconstituted penicillin solution, local venous irritation, and repeated infusions through the same site. More common at higher concentrations and with prolonged peripheral IV access. Strategies: dilute adequately (infuse in ≥50 mL NS), rotate IV sites every 48–72 hours, consider midline catheter or PICC for courses >3–5 days. |
|
Fever (drug fever)
|
Immunological | Non-infectious fever occurring during penicillin therapy (usually after 7–10 days of treatment). Part of a broader drug hypersensitivity syndrome. Diagnosis of exclusion — must rule out inadequately treated infection, abscess, or other causes of fever before attributing to drug fever. Resolves within 48–72 hours of stopping penicillin. |
|
Eosinophilia
|
Haematological | Mild peripheral eosinophilia (>500/μL) may develop during prolonged penicillin courses. Usually asymptomatic and self-limiting. May herald more serious hypersensitivity (interstitial nephritis, serum sickness-like reaction) — monitor if >10% eosinophils or if accompanied by rash, fever, or rising creatinine. |
| Adverse Effect | Dose Threshold |
| GI effects (diarrhoea, nausea) | More common at higher total daily doses (>12 MU/day) and with prolonged courses. |
| Phlebitis | More common with concentrated solutions (>100,000 units/mL for IV push) and at higher total daily doses. |
| Electrolyte disturbance (Na⁺/K⁺) | Clinically significant at ≥12 MU/day. See Cautions section. |
| Neurotoxicity (seizures, myoclonus) | Risk increases significantly at doses >20 MU/day, especially in renal impairment. See Serious Adverse Effects. |
| Serious Adverse Effect | Approximate Frequency | Details | Action Required |
|
⚠️ Anaphylaxis (IgE-mediated Type I hypersensitivity)
|
1–5 per 10,000 treatment courses (~0.01–0.05%); fatality rate ~1 per 50,000–100,000 treatment courses
|
The most feared adverse effect of penicillin. Onset: within seconds to 60 minutes of penicillin administration (any route — IV, IM, or even skin test). Classic features: urticaria, angioedema (swelling of face/lips/tongue/throat), bronchospasm (wheeze, dyspnoea), laryngeal oedema (stridor), hypotension, cardiovascular collapse, loss of consciousness, cardiac arrest. Risk is highest with parenteral administration (IV > IM). Risk does NOT increase with repeated penicillin courses — anaphylaxis can occur on first exposure (via prior environmental sensitisation) or on any subsequent exposure. ℹ️ The risk of fatal anaphylaxis must be weighed against the risk of NOT treating with penicillin (e.g., death from untreated meningitis, progressive RHD). For most serious infections, the benefit of penicillin vastly outweighs the small anaphylaxis risk — but preparedness for anaphylaxis management is mandatory.
|
⛔ Immediate recognition and treatment.Adrenaline (epinephrine) 1:1000 (1 mg/mL) IM — the first-line treatment for anaphylaxis. Adult dose: 0.5 mL (0.5 mg) IM into the anterolateral thigh. Paediatric dose: 0.01 mL/kg (0.01 mg/kg) IM, max 0.3 mL (<6 years), 0.5 mL (≥6 years). Repeat every 5–15 minutes if needed. Lay the patient flat with legs elevated (unless contraindicated by respiratory distress). Simultaneously: high-flow oxygen, IV access, IV fluids (NS 500–1000 mL bolus adult; 20 mL/kg child), IV antihistamine (chlorpheniramine 10 mg or diphenhydramine 50 mg), IV hydrocortisone 200 mg (adult) — for prevention of biphasic reaction. If bronchospasm: nebulised salbutamol. If cardiac arrest: CPR + adrenaline IV 1 mg. Observe for at least 6 hours post-anaphylaxis (risk of biphasic reaction in ~5–20%). Adrenaline availability: ✅ Widely available in India (ampoules stocked at virtually all healthcare facilities). Every injection room administering penicillin MUST have adrenaline and anaphylaxis kit immediately accessible. ⚠️ Report to PvPI.
|
|
⚠️ Serum sickness-like reaction (Type III hypersensitivity)
|
~1–2% (more common with prolonged courses >10 days)
|
Immune complex-mediated reaction. Onset: 7–21 days after starting penicillin (delayed). Presents as: fever, urticaria or maculopapular rash, arthralgia/arthritis (polyarticular, migratory), lymphadenopathy, proteinuria, and occasionally glomerulonephritis. Laboratory: low C3/C4 complement, elevated ESR, circulating immune complexes.
|
Stop penicillin. Supportive treatment: NSAIDs for joint pain, antihistamines for urticaria, short course of prednisolone (0.5–1 mg/kg/day × 5–7 days) for severe symptoms. Usually self-limiting within 1–3 weeks of drug discontinuation. Document as “serum sickness-like reaction to penicillin” — this does NOT indicate IgE-mediated allergy, but penicillin should be avoided in future unless formally tested. ⚠️ Report to PvPI. |
|
⚠️ Penicillin neurotoxicity (seizures, myoclonus, encephalopathy)
|
Rare at standard doses; significant at high doses (>20 MU/day) in renal impairment
|
Dose-dependent adverse effect caused by GABA-A receptor antagonism at high CNS concentrations. Presents as: multifocal myoclonus (earliest sign — involuntary muscle jerking), generalised tonic-clonic seizures, confusion, lethargy, encephalopathy, hallucinations, coma. Risk factors: (a) high total daily dose (>20 MU/day); (b) renal impairment (reduced clearance → drug accumulation); © pre-existing CNS disease (meningitis, brain abscess — inflamed meninges increase CSF drug levels); (d) elderly patients; (e) intrathecal administration (absolute contraindication — see Contraindications). Occurs most commonly in endocarditis and neurosyphilis patients receiving 18–24 MU/day with concurrent renal function decline during the treatment course. |
⛔ Stop or reduce the dose immediately. Seizure management: IV diazepam 5–10 mg (adult) or IV midazolam 2–5 mg. If refractory: IV phenytoin or levetiracetam. Check renal function — adjust penicillin dose for renal impairment. Consider haemodialysis for severe toxicity with renal failure (penicillin is dialysable). ⚠️ No specific antidote exists for penicillin neurotoxicity — management is dose reduction + supportive care. ⚠️ Report to PvPI.
|
|
⚠️ Acute interstitial nephritis (AIN)
|
Rare (~0.1–0.5% of prolonged courses)
|
Immune-mediated allergic reaction affecting renal tubules and interstitium. Onset: usually 1–4 weeks after starting penicillin. Classic triad (present in <30% of cases): fever, rash, eosinophilia. Laboratory: rising serum creatinine, eosinophiluria (urine eosinophils on Wright stain), mild proteinuria, sterile pyuria. May progress to acute kidney injury requiring dialysis if unrecognised.
|
Stop penicillin. Renal function usually recovers within weeks of drug discontinuation (most cases are reversible). Corticosteroids (prednisolone 1 mg/kg/day × 1–2 weeks then taper) may accelerate recovery in severe cases — evidence is mixed. Nephrology consultation for severe AKI. Avoid ALL penicillins in the future — the reaction is likely to recur on re-exposure. ⚠️ Report to PvPI. |
|
⚠️ Coombs-positive haemolytic anaemia
|
Very rare (<0.1%) — reported with high-dose prolonged IV courses (>10 MU/day × >2 weeks)
|
Penicillin binds to red blood cell membranes → acts as a hapten → IgG anti-penicillin antibodies bind → complement activation → extravascular haemolysis. Presents as: progressive anaemia, jaundice (indirect hyperbilirubinaemia), reticulocytosis, positive direct Coombs test (DAT). | Stop penicillin. Haemolysis resolves within days to weeks of discontinuation. Transfusion for severe anaemia. Corticosteroids may help. Monitor Hb, reticulocyte count, LDH, haptoglobin, bilirubin. ⚠️ Report to PvPI. |
|
⚠️ Clostridioides difficile infection (CDI)
|
Uncommon with narrow-spectrum penicillin G (more common with aminopenicillins and cephalosporins)
|
Antibiotic-associated disruption of gut flora → C. difficile overgrowth → toxin-mediated colitis. Presents as: watery diarrhoea (≥3 unformed stools/day), abdominal cramps, fever, leucocytosis. Severe cases: toxic megacolon, perforation, sepsis.
|
Stop the offending antibiotic if possible (or switch to a narrower-spectrum agent). Diagnose with stool C. difficile toxin assay (GDH + toxin A/B EIA or NAAT). Treat with: oral vancomycin 125 mg QID × 10 days (first-line for all severity in current guidelines) or oral/IV metronidazole 500 mg TDS × 10 days (second-line; still commonly used first-line in Indian practice due to cost). Fidaxomicin 200 mg BD × 10 days — available in India at limited centres, expensive. ⚠️ Report to PvPI for severe cases.
|
|
⚠️ Hoigné reaction (pseudo-anaphylaxis — depot penicillin formulations only)
|
1–3% of benzathine/procaine penicillin IM injections (some series report up to 5%)
|
See detailed description in Cautions section. Non-allergic, non-fatal acute psychomotor reaction occurring within seconds to minutes of IM depot penicillin injection. ⚠️ Must be differentiated from true anaphylaxis — Hoigné reaction does NOT have urticaria, angioedema, bronchospasm, or hypotension.
|
Supportive: reassurance, calm environment, benzodiazepine for severe agitation (diazepam 5–10 mg IV or midazolam 2 mg IM). Resolves spontaneously within 15–30 minutes. Does NOT contraindicate future penicillin use. ⚠️ Do NOT administer adrenaline unless anaphylaxis features are present. |
|
Jarisch-Herxheimer reaction (syphilis treatment only)
|
10–35% of early syphilis treatment; ~2% of late syphilis treatment
|
See detailed description in Cautions section. Not a drug adverse effect per se — it is a host response to treponemal die-off. | Supportive: paracetamol, fluids. Does NOT require stopping penicillin. Obstetric monitoring in pregnant women. |
|
Hyperkalaemia (potassium salt only — at high doses)
|
Dose-dependent; clinically relevant at >12 MU/day of the potassium salt
|
Each 1 MU potassium salt = ~1.7 mEq K⁺. At 24 MU/day = ~41 mEq K⁺/day. In patients with renal impairment, this can cause life-threatening hyperkalaemia (cardiac arrhythmias, cardiac arrest). |
⚠️ Preferentially use the sodium salt (standard in India). Monitor serum K⁺ daily at high doses. ECG monitoring if K⁺ >5.5 mEq/L. Treat hyperkalaemia per standard protocol (calcium gluconate, insulin + glucose, salbutamol nebulisation, ion-exchange resin, dialysis).
|
| Toxicity | Antidote | Dose | Availability in India |
|
Anaphylaxis
|
Adrenaline (epinephrine) 1:1000 IM
|
Adult: 0.5 mg IM; Paediatric: 0.01 mg/kg IM (max 0.3–0.5 mg). Repeat every 5–15 min. |
✅ Widely available — must be present at every injection site.
|
|
Penicillin neurotoxicity (seizures)
|
Benzodiazepines (diazepam, midazolam)
|
Diazepam 5–10 mg IV (adult); 0.2–0.3 mg/kg IV (child). Midazolam 2–5 mg IV/IM. |
✅ Widely available.
|
|
Hyperkalaemia (from potassium salt)
|
Calcium gluconate (cardiac membrane stabiliser) + insulin-glucose (shifts K⁺ intracellularly)
|
Calcium gluconate 10%: 10 mL IV over 2–5 min (adult). Insulin 10 units + 25 g glucose IV. |
✅ Widely available.
|
|
Acute interstitial nephritis
|
No specific antidote. Corticosteroids may accelerate recovery.
|
Prednisolone 1 mg/kg/day × 1–2 weeks, then taper. | ✅ Available. |
| Parameter | Grade | Details |
|
Penicillin allergy history
|
MANDATORY
|
⚠️ Ask EVERY patient specifically: “Have you ever had a reaction to penicillin or any antibiotic? What happened? How soon after taking the medicine?” Document the response. Differentiate IgE-mediated (anaphylaxis, urticaria within 1 hour) from non-IgE (delayed rash, GI upset). |
|
Renal function (serum creatinine, eGFR)
|
RECOMMENDED (MANDATORY for high-dose IV regimens >12 MU/day)
|
Essential for dose adjustment in high-dose regimens (endocarditis, meningitis, neurosyphilis). For benzathine penicillin IM prophylaxis or single-dose syphilis treatment, renal function check is not mandatory. |
|
Serum electrolytes (Na⁺, K⁺)
|
RECOMMENDED for high-dose IV crystalline penicillin (>12 MU/day)
|
Baseline values important for detecting drug-related electrolyte disturbance. Correct hypokalaemia before starting (risk of penicillin neurotoxicity is potentiated by electrolyte abnormalities). |
|
CBC with differential
|
RECOMMENDED
|
Baseline for detecting subsequent haematological adverse effects (eosinophilia, haemolytic anaemia, neutropaenia — all rare). |
|
Anaphylaxis kit availability
|
MANDATORY
|
⚠️ Before EVERY penicillin injection (IV, IM — any salt form): confirm that adrenaline (epinephrine) injection, syringes, IV cannula, IV fluids, and resuscitation equipment are immediately available at the injection site. |
|
Infection-specific investigations
|
MANDATORY — specific to the indication
|
Blood cultures (before starting — for endocarditis, sepsis, meningitis); LP (for meningitis, neurosyphilis); echocardiography (for endocarditis, RF); RPR/VDRL + treponemal test (for syphilis); wound cultures (for gas gangrene). See individual indications in Part 2. |
| Parameter | Surrogate |
| Renal function | If serum creatinine/eGFR cannot be measured: ask about known kidney disease, diabetes, oedema, reduced urine output. If high-risk factors for renal impairment exist, reduce dose empirically and refer for testing. For benzathine penicillin RF prophylaxis, renal function is not critical (very low systemic levels). |
| Serum electrolytes | If electrolytes cannot be measured at high IV doses: monitor for clinical signs — muscle weakness, palpitations, arrhythmia (hyperkalaemia); confusion, seizures (hyponatraemia or neurotoxicity). ECG if available. |
| Allergy assessment | Careful verbal history is the minimum acceptable standard. If history is unclear and the indication is critical, consider a supervised test dose (see below). |
| Timing | Monitoring | Details |
|
During and 30 minutes after EVERY IM injection (benzathine/procaine penicillin)
|
Observation for anaphylaxis and Hoigné reaction | Patient must remain in the clinic/injection room. Have adrenaline and resuscitation equipment ready. |
|
During IV infusion
|
IV site inspection; vital signs | Check for phlebitis, extravasation, infusion reactions. Monitor heart rate and blood pressure during infusion (especially first dose). |
|
Daily (for high-dose IV courses)
|
Renal function (creatinine), serum electrolytes (Na⁺, K⁺), neurological status | ⚠️ Check creatinine daily or every 48 hours during high-dose IV therapy (endocarditis, meningitis, neurosyphilis). Monitor for myoclonus (earliest sign of neurotoxicity). Monitor input-output chart (urine output). |
|
Day 3–5 of treatment
|
Clinical response assessment | Is the patient improving? Are cultures becoming negative? If not improving, reassess diagnosis and antibiotic choice. |
|
Weekly (for prolonged courses >2 weeks)
|
CBC with differential, renal function, LFT | Monitor for: eosinophilia (drug allergy), neutropaenia (rare — prolonged high-dose courses), rising creatinine (interstitial nephritis — fever + rash + eosinophilia + rising creatinine = classic triad), Coombs-positive haemolytic anaemia (progressive anaemia with reticulocytosis). |
| Timing | Monitoring | Details |
|
At each injection visit (every 3–4 weeks)
|
Enquire about symptoms of RF recurrence (fever, joint pain, chorea, new cardiac symptoms), adverse effects (injection site problems), and adherence | Brief clinical assessment at each visit. Document injection given (date, dose, site, batch number). |
|
Annually
|
Echocardiography | Assess progression or regression of valvular disease. Essential for guiding duration of prophylaxis and surgical planning. |
|
As needed
|
ASO titre, CRP/ESR | Only if acute RF recurrence is suspected (not routine monitoring). |
| Question | Answer |
|
“Can I take this with my other medicines?”
|
“This medicine is generally safe with most other medicines. Tell your doctor about all medicines you are taking. If you are on a blood-thinning medicine (warfarin), your doctor may need to check your blood more often.” |
|
“Can I receive this injection during fasting (Ramadan/Navratri)?”
|
“Yes — an injection does not break a religious fast according to most Islamic and Hindu scholarly opinions. You can receive your injection during fasting periods without concern.” |
|
“Will this affect my ability to drive or work?”
|
“No — this medicine does not cause drowsiness or dizziness. You can drive and work normally. You may have some pain at the injection site for a day or two.” |
|
“Is this medicine habit-forming?”
|
“No — antibiotics are not addictive.” |
|
“Can I stop once I feel better?”
|
“⚠️ NO — especially for RF prophylaxis. This injection is to PREVENT future disease, not to treat current symptoms. You must continue even when you feel perfectly well. For infection treatment, complete the full course as prescribed.”
|
|
“The injection is very painful — can anything be done?”
|
“Yes — your doctor or nurse can use a numbing cream (EMLA) on the skin before the injection. Warming the medicine to room temperature, using a slightly larger needle (21G), and injecting slowly also help reduce pain. Deep breathing or distraction (music, conversation) during the injection can help.” |
| Concern | Guidance |
|
Cost-driven non-adherence
|
“Benzathine penicillin is one of the cheapest medicines in India — usually ₹15–50 per injection. It is available at government hospitals for free. Ask about Jan Aushadhi pharmacies for the lowest price.” |
|
Supply shortage (benzathine penicillin)
|
“⚠️ Benzathine penicillin has been in short supply in India in recent years. If your local pharmacy or hospital does not have it, ask the doctor about alternatives: (a) Check with other pharmacies, district hospital, or medical college hospital; (b) Oral penicillin V (Pen V) 250 mg twice daily can be used as a temporary substitute — but the daily tablets must be taken EVERY DAY without fail; © Your doctor may prescribe oral erythromycin as an alternative.” |
|
Rural access
|
“If you live far from the clinic, ask whether an ASHA worker or ANM can visit your village to give the injection. Some NVHCP centres provide outreach injection services.” |
|
Temperature-sensitive storage
|
“The injection powder does not need a fridge — keep it at room temperature, below 30°C, in a dry place.” |
|
Stigma (syphilis)
|
“Syphilis is a common infection that can happen to anyone. It is completely curable with one injection. Treatment is confidential. Your partner should also be tested and treated.” |
| Brand Name | Manufacturer | Strength | Availability |
|
Penidure C (crystalline component)
|
Wyeth/Pfizer (now various licensed manufacturers) | Part of combination vials (see FPP below) | Widely available |
|
G-Penicillin / Penicillin G Sodium (generic)
|
Multiple Indian manufacturers (Alkem, Biochem, Cadila, Hindustan Antibiotics Ltd [HAL]) | 5 lakh units, 10 lakh units, 20 lakh units, 50 lakh units |
Widely available — stocked in most government and private hospitals. HAL (public sector) supplies to government hospitals at subsidised rates.
|
| Brand Name | Manufacturer | Strength | Availability |
|
Penidure LA
|
Wyeth/Pfizer (now various manufacturers) | 6 lakh units (600,000 IU); 12 lakh units (1.2 MU) |
⚠️ INTERMITTENT AVAILABILITY. Chronic supply shortage since ~2016. Availability fluctuates — check with local pharmacy, district hospital, or state drug warehouse. When available, Penidure LA is the most recognised brand.
|
|
Pencom-12
|
Alkem Laboratories | 12 lakh units (1.2 MU) |
Moderate availability — urban pharmacies and hospital pharmacies.
|
|
Benzapen
|
Various manufacturers | 12 lakh units; 24 lakh units |
Limited availability — variable stocking.
|
|
Generic benzathine penicillin
|
Multiple manufacturers (HAL, others) | 6 lakh units; 12 lakh units | Government hospital supply — availability varies by state and supply chain. |
| Brand Name | Manufacturer | Composition | Availability |
|
Penidure Forte / FPP
|
Various manufacturers | Crystalline penicillin + Procaine penicillin (e.g., 1 lakh + 3 lakh = 4 lakh total) |
Widely available — commonly stocked in PHC/CHC pharmacies and district hospitals. The most accessible injectable penicillin formulation in rural India.
|
| Formulation | Strength | Approximate Price Range (INR) | Notes |
|
Crystalline penicillin (sodium) injection
|
5 lakh units (500,000 IU) vial | ₹8–20 per vial | Very affordable. Government supply: ₹5–10. |
| 10 lakh units (1 MU) vial | ₹12–30 per vial | Most commonly used. Government supply: ₹8–15. | |
| 20 lakh units (2 MU) vial | ₹20–50 per vial | ||
| 50 lakh units (5 MU) vial | ₹40–80 per vial | Reduces number of vials for high-dose therapy. | |
|
Benzathine penicillin injection
|
6 lakh units (600,000 IU) vial | ₹15–40 per vial | ⚠️ Price may be higher during supply shortages. |
| 12 lakh units (1.2 MU) vial | ₹25–60 per vial | Standard adult RF prophylaxis dose. Government supply: ₹15–25. | |
| 24 lakh units (2.4 MU) vial | ₹40–90 per vial | For syphilis treatment. Less commonly stocked. | |
|
Procaine penicillin / FPP injection
|
4 lakh units vial (FPP) | ₹10–25 per vial | Very affordable. Widely available. |
|
Jan Aushadhi
|
Various strengths | ₹5–20 per vial (lowest available) |
| Scenario | Estimated Cost |
|
RF prophylaxis — 1 year (benzathine penicillin 1.2 MU every 3 weeks × ~17 injections)
|
Branded: ₹425–1,020/year. Generic/Government: ₹255–425/year. Jan Aushadhi: ₹85–340/year. ℹ️ One of the most cost-effective interventions in medicine — preventing progressive RHD that would otherwise require ₹3–10 lakh valve surgery.
|
|
Syphilis (early) — single dose benzathine penicillin 2.4 MU
|
₹40–90 (single injection). |
|
Syphilis (late latent) — 3 weekly doses of 2.4 MU
|
₹120–270 (3 injections). |
|
Neurosyphilis — 14 days IV crystalline penicillin 24 MU/day
|
Crystalline penicillin: ~5 vials of 5 MU/day × 14 days = 70 vials × ₹40–80 = ₹2,800–5,600 (drug cost only; hospital admission costs additional). |
|
Endocarditis — 4 weeks IV crystalline penicillin 18 MU/day
|
~4 vials of 5 MU/day × 28 days = 112 vials × ₹40–80 = ₹4,480–8,960 (drug cost only). |
|
Meningitis — 7 days IV crystalline penicillin 24 MU/day
|
~5 vials of 5 MU/day × 7 days = 35 vials × ₹40–80 = ₹1,400–2,800 (drug cost only). |
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Help us improve our clinical database for the medical community.